CCRA® — Certified Clinical Research Associate — Questions and Answers

Question 1: What information must appear on investigational product labels per GCP and regulatory requirements?

Only the product name and lot number
Subject name, date of birth, and insurance information
Trial number, protocol ID, subject/dose information, storage conditions, sponsor contact, and the statement 'For Clinical Trial Use Only' (Correct answer)
Commercial product name and manufacturer address

Correct answer: Trial number, protocol ID, subject/dose information, storage conditions, sponsor contact, and the statement 'For Clinical Trial Use Only'

GCP IP labels must include the clinical trial identification, dosing information, storage requirements, sponsor or manufacturer contact, and the mandatory statement that the product is for investigational use only.

Question 2: A 'temperature excursion' for investigational product occurs when:

The IP dispensing log shows missing entries
The IP is shipped to an unapproved country
The IP expiration date passes without disposal
IP storage conditions deviate outside the protocol-specified temperature range (Correct answer)

Correct answer: IP storage conditions deviate outside the protocol-specified temperature range

A temperature excursion is when IP is exposed to temperatures outside the specified storage range; the sponsor's medical/quality team must evaluate whether the affected IP remains usable.

Question 3: Which regulation requires informed consent to be obtained in a language understandable to the subject?

21 CFR Part 56
45 CFR Part 46
ICH E6(R2) Section 4.8
21 CFR Part 50 (Correct answer)

Correct answer: 21 CFR Part 50

21 CFR Part 50 specifies that the information given to subjects must be in language understandable to the subject or their legally authorized representative.

Question 4: What is the purpose of investigational product (IP) accountability at a clinical trial site?

To ensure accurate records of all IP received, dispensed, returned, and destroyed to verify subject compliance and prevent misuse (Correct answer)
To monitor competitive product use by subjects
To calculate the sponsor's manufacturing costs
To track IP shipment transit times

Correct answer: To ensure accurate records of all IP received, dispensed, returned, and destroyed to verify subject compliance and prevent misuse

IP accountability requires maintaining records showing the disposition of every unit of investigational product to confirm it was used only for trial purposes and that subjects received the correct doses.

Question 5: A CRA discovers that a site has been using an expired version of the informed consent form. What is the MOST immediate action?

Halt all trial procedures at the site
Terminate the investigator immediately
Document the finding and require re-consent using the current IRB-approved form (Correct answer)
Submit a serious breach report to the IRB without sponsor involvement

Correct answer: Document the finding and require re-consent using the current IRB-approved form

The CRA must document the deviation and work with the site to re-consent affected subjects using the current approved form, while reporting to the sponsor per the monitoring plan.

Question 6: A sponsor-CRA learns that an investigator has not reported a serious adverse event (SAE) to the IRB within the required timeframe. What must the CRA do?

Report the SAE to the IRB directly on behalf of the investigator
Close the site immediately and notify the FDA
Document the finding, notify the investigator of the obligation, and escalate to sponsor management per the monitoring plan (Correct answer)
Amend the protocol to remove the SAE reporting requirement

Correct answer: Document the finding, notify the investigator of the obligation, and escalate to sponsor management per the monitoring plan

The CRA must document the deviation, remind the investigator of their reporting obligation, and escalate to sponsor management as specified in the monitoring plan.

Question 7: What qualifies as a 'source document' in a clinical trial?

Only the Case Report Form (CRF)
Electronic data capture system printouts only
The protocol and amendments only
Original records and certified copies of original information including medical records, lab reports, and subject diaries (Correct answer)

Correct answer: Original records and certified copies of original information including medical records, lab reports, and subject diaries

Source documents are original records from which subject data are first captured, including hospital records, clinic charts, laboratory notes, diaries, pharmacy records, and imaging results.

Question 8: During IP reconciliation at a monitoring visit, the CRA discovers more units were dispensed than accounted for in subject dosing records. The FIRST action is to:

Destroy the excess IP immediately
Investigate the discrepancy with site staff and document findings; notify the sponsor if unresolved (Correct answer)
Report the site to the FDA immediately
Assume it is a counting error and move on

Correct answer: Investigate the discrepancy with site staff and document findings; notify the sponsor if unresolved

IP discrepancies must be investigated with site staff to identify the cause; if unexplained, the sponsor must be notified, and depending on severity, regulatory reporting or a for-cause audit may be required.

Question 9: The Declaration of Helsinki, as it relates to clinical research, emphasizes that:

Subjects may be enrolled without consent if the research has societal benefit
Investigators are not required to disclose conflicts of interest
The well-being of individual research subjects must take precedence over the interests of science and society (Correct answer)
Placebo-controlled trials are always unethical when existing treatment is available

Correct answer: The well-being of individual research subjects must take precedence over the interests of science and society

The Declaration of Helsinki places the health and rights of individual subjects above scientific and societal interests, forming an ethical cornerstone of clinical research.

Question 10: Which Belmont Report principle requires that the benefits of research be maximized and harms minimized?

Respect for persons
Justice
Autonomy
Beneficence (Correct answer)

Correct answer: Beneficence

The principle of beneficence obligates researchers to maximize possible benefits and minimize possible harms when conducting research with human subjects.

Question 11: A CRA notices that a site has been enrolling subjects without obtaining updated ICF signatures after a protocol amendment. What is the CRA's immediate obligation?

Ignore it if no serious adverse events have occurred
Halt the trial immediately without notifying anyone
Document the finding as a protocol deviation and report it to the sponsor (Correct answer)
Re-consent all affected subjects personally without sponsor notification

Correct answer: Document the finding as a protocol deviation and report it to the sponsor

Failure to obtain updated consent after an amendment is a protocol deviation that must be documented and reported to the sponsor per GCP guidelines.

Question 12: What phase is the patient NOT healthy?

At phase 8
At phase 98
At phase 2 (Correct answer)
At phase 4

Correct answer: At phase 2

In clinical trials, Phase 1 studies typically involve a small group of healthy volunteers to assess drug safety and dosage. Phase 2 studies, however, involve a larger group of patients who actually have the condition the drug is intended to treat. Therefore, patients in Phase 2 are generally not healthy, as the drug's efficacy and further safety are being evaluated in the target population.

Question 13: If a site's pharmacy refrigerator storing investigational product fails overnight, the CRA should advise the site to:

Continue dispensing the product since one night is unlikely to matter
Replace the IP from their own supply
Immediately discard all affected IP without notifying the sponsor
Document the excursion details (temperature range, duration) and contact the sponsor's clinical supply team for disposition guidance before dispensing affected product (Correct answer)

Correct answer: Document the excursion details (temperature range, duration) and contact the sponsor's clinical supply team for disposition guidance before dispensing affected product

Temperature excursions must be fully documented and assessed by the sponsor's supply and quality teams before any affected product is used; dispensing compromised IP could harm subjects.

Question 14: Risk-Based Monitoring (RBM) focuses monitoring resources primarily on:

Sites with the highest enrollment numbers
Identified critical data and processes with the greatest patient risk potential (Correct answer)
Regulatory submission timelines
Sites closest geographically to the sponsor

Correct answer: Identified critical data and processes with the greatest patient risk potential

RBM, as endorsed by ICH E6(R2) and FDA guidance, prioritizes monitoring efforts based on identified risks to subject safety and data integrity rather than routine 100% source data verification.

Question 15: The 'data lock' in a clinical trial refers to:

The EDC system going offline for maintenance
Encrypting the trial database at study startup
The point at which the database is closed to further changes in preparation for statistical analysis (Correct answer)
Locking physical CRF binders at the site

Correct answer: The point at which the database is closed to further changes in preparation for statistical analysis

Database lock is the formal process of freezing the clinical database after all data queries are resolved, confirming the dataset is complete and ready for unblinded statistical analysis.

Question 16: Which ICH guideline specifically addresses the statistical principles for the design and analysis of confirmatory clinical trials?

ICH E3
ICH E9 (Correct answer)
ICH E8
ICH E6

Correct answer: ICH E9

ICH E9 (Statistical Principles for Clinical Trials) provides guidance on statistical methodology for confirmatory efficacy and safety trials.

Question 17: What is the minimum required retention period for clinical trial essential documents under FDA regulations?

5 years after database lock
2 years after a marketing application is approved, or 2 years after the IND is terminated if no application is filed (Correct answer)
10 years after study completion
2 years after the last subject's last visit

Correct answer: 2 years after a marketing application is approved, or 2 years after the IND is terminated if no application is filed

Under 21 CFR 312.62, investigational records must be retained for 2 years following the date a marketing application is approved, or 2 years after IND discontinuation if no application is submitted.

Question 18: Which document defines the objectives, design, methodology, statistical considerations, and organization of a clinical trial?

The Investigator's Brochure
The Clinical Study Report
The Case Report Form
The clinical trial protocol (Correct answer)

Correct answer: The clinical trial protocol

The clinical trial protocol is the master document that provides the scientific rationale, objectives, design, methodology, and statistical plan for the study.

Question 19: Which regulatory document grants the FDA authority to inspect clinical investigators conducting trials under an IND?

21 CFR Part 312 — IND Regulations (Correct answer)
21 CFR Part 54 — Financial Disclosure
21 CFR Part 820 — Quality System Regulation
21 CFR Part 11 — Electronic Records

Correct answer: 21 CFR Part 312 — IND Regulations

21 CFR Part 312 establishes IND requirements and grants FDA the authority to inspect clinical investigators and their records.

Question 20: What is Clinical trial management system (CTMS)?

An application filed with the FDA after completion of pre-clinical and prior to human testing
Whether humans and animals show a significantly different response to the drug and to establish safe clinical dosage range
CRA will enter trip reports, track protocol deviations, house all site information (Correct answer)
Via telephone

Correct answer: CRA will enter trip reports, track protocol deviations, house all site information

A Clinical Trial Management System (CTMS) is a software system used by pharmaceutical and biotechnology companies, as well as contract research organizations (CROs), to manage and track clinical trials. It serves as a central repository for trial-related information, enabling CRAs to enter trip reports, monitor site performance, track protocol deviations, manage documents, and oversee overall study progress.

Question 21: Which regulatory guidance specifically supports a reduced and risk-adapted approach to source data verification?

FDA Guidance for Industry: Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring (2013) (Correct answer)
ICH E8 General Considerations for Clinical Studies
21 CFR Part 50 Informed Consent
FDA Guidance on IND Applications (2012)

Correct answer: FDA Guidance for Industry: Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring (2013)

The FDA's 2013 RBM guidance explicitly endorses a risk-based approach to monitoring including targeted SDV focused on critical data rather than 100% verification of all data.

Question 22: At close-out, what is the required minimum document retention period for clinical trial records at an investigational site in the US under FDA regulations?

5 years after the last subject visit
10 years from database lock
1 year after study completion
2 years following marketing approval or discontinuation of the IND (Correct answer)

Correct answer: 2 years following marketing approval or discontinuation of the IND

Per 21 CFR 312.62, investigators must retain records for 2 years following the date of FDA marketing approval or the date the IND is withdrawn or the investigation discontinued.

Question 23: What does 'query resolution' involve in clinical data management?

Identifying, clarifying, and correcting data discrepancies or missing data in CRFs through a formal communication process (Correct answer)
Answering protocol questions from investigators
Resolving financial payment disputes between sponsor and sites
Resolving IRB approval queries from site staff

Correct answer: Identifying, clarifying, and correcting data discrepancies or missing data in CRFs through a formal communication process

Query resolution is the process by which data managers or CRAs flag data issues in the CRF/EDC, sites investigate and correct the data, and the resolution is documented with an explanation.

Question 24: What is the purpose of a 'double-blind dummy' (matching placebo or active control) in a clinical trial?

To satisfy FDA labeling requirements
To provide a backup supply of investigational product
To maintain blinding by ensuring all treatment arms have identical appearance, so neither subjects nor site staff can distinguish active from placebo (Correct answer)
To reduce manufacturing costs

Correct answer: To maintain blinding by ensuring all treatment arms have identical appearance, so neither subjects nor site staff can distinguish active from placebo

Matching placebos or dummy controls are formulated to be identical in appearance, taste, and texture to the active product, preserving blinding integrity throughout the trial.

Question 25: Conflict of interest is a risk factor for scientific misconduct in clinical research investigations.

No
Yes (Correct answer)

Correct answer: Yes

Yes, a conflict of interest is a significant risk factor for scientific misconduct in clinical research investigations. When researchers, sponsors, or institutions have financial or other personal interests that could improperly influence the design, conduct, or reporting of a study, it can compromise the integrity of the research and the safety of participants. Transparency and strict management of conflicts of interest are crucial to maintaining research ethics and credibility.

Question 26: During a routine monitoring visit, the CRA discovers that the site has been enrolling subjects who do not meet the inclusion criteria. What is the FIRST action the CRA should take?

Immediately suspend the trial at the site
Notify the IRB directly without informing the sponsor
Withdraw the non-compliant subjects from the study
Document the finding and discuss it with the investigator during the visit (Correct answer)

Correct answer: Document the finding and discuss it with the investigator during the visit

The CRA should document the protocol deviation and discuss it with the investigator to understand the root cause before escalating per the monitoring plan.

Question 27: How long after its occurrence must a sponsor report a suspected unexpected serious adverse reaction (SUSAR) to the FDA for fatal or life-threatening events?

Within 7 calendar days (Correct answer)
Within 24 hours
Within 15 calendar days
Within 30 calendar days

Correct answer: Within 7 calendar days

Fatal or life-threatening SUSARs must be reported to the FDA within 7 calendar days of the sponsor's first receipt of information, per 21 CFR 312.32.

Question 28: Under 21 CFR Part 312, an Investigational New Drug (IND) application must be submitted to the FDA before:

Initiating a clinical investigation of a new drug in humans (Correct answer)
Publishing preclinical study results
Applying for NDA approval
Conducting Phase IV post-marketing studies

Correct answer: Initiating a clinical investigation of a new drug in humans

An IND must be in effect before a sponsor ships an investigational drug across state lines or begins clinical studies in humans.

Question 29: A 'data reconciliation' process between the safety database and the clinical database is performed to:

Confirm randomization assignments match enrollment logs
Reconcile laboratory values with imaging data
Ensure all adverse events captured in the safety system are accurately reflected in the clinical database and vice versa (Correct answer)
Match financial invoices with subject visit data

Correct answer: Ensure all adverse events captured in the safety system are accurately reflected in the clinical database and vice versa

Safety-to-clinical database reconciliation ensures that all adverse events, medications, and safety data are consistently recorded in both the safety reporting system and the clinical EDC.

Question 30: What is the primary regulatory framework governing the protection of human research subjects in federally funded research in the United States?

The Common Rule (45 CFR Part 46) (Correct answer)
The Health Insurance Portability and Accountability Act (HIPAA)
The International Conference on Harmonisation (ICH) E6
The Food, Drug, and Cosmetic Act (FD&C Act)

Correct answer: The Common Rule (45 CFR Part 46)

The Common Rule (45 CFR Part 46) is the primary federal regulation for protecting human subjects in research conducted or supported by federal agencies.

Question 31: Under FDA regulations, which document defines the sponsor's delegation of trial-related duties to a CRO?

Monitoring Plan
Clinical Trial Agreement
Written Transfer of Obligations (Correct answer)
Protocol Amendment

Correct answer: Written Transfer of Obligations

21 CFR Part 312 requires a written transfer of obligations document when a sponsor transfers any trial duties to a CRO.

Question 32: What is the primary purpose of a Form FDA 1572 (Statement of Investigator)?

To authorize IRB approval
To document the investigator's commitments and qualifications to conduct the trial per FDA regulations (Correct answer)
To report adverse events to the sponsor
To request drug shipment from the manufacturer

Correct answer: To document the investigator's commitments and qualifications to conduct the trial per FDA regulations

FDA Form 1572 is a legal agreement in which the investigator commits to conducting the trial per the protocol, GCP, and applicable regulations, and lists key personnel and IRB information.

Question 33: A 'Certificate of Analysis' (CoA) for investigational product is used primarily to verify:

Site staff qualifications
IRB approval dates
Drug identity, purity, potency, and quality (Correct answer)
Subject eligibility criteria

Correct answer: Drug identity, purity, potency, and quality

A CoA documents that the investigational product meets specified quality attributes including identity, purity, potency, and other release specifications.

Question 34: In clinical trials, 'outcome' for an adverse event typically refers to which of the following classifications?

Mild, moderate, severe, life-threatening, fatal
Expected, unexpected, serious, non-serious
Related, possibly related, unrelated, unknown
Recovered/resolved, recovering/resolving, not recovered/not resolved, recovered with sequelae, fatal, unknown (Correct answer)

Correct answer: Recovered/resolved, recovering/resolving, not recovered/not resolved, recovered with sequelae, fatal, unknown

Standard AE outcome categories describe the resolution status of the event: recovered, recovering, not recovered, recovered with sequelae, fatal, or unknown.

Question 35: Under the ALCOA principles for data integrity in clinical trials, what does the 'A' stand for and why is it critical?

Audited — every record must be independently verified by the CRA
Automated — electronic systems must generate all entries
Anonymous — subject identifiers must be removed from all records
Accurate — data must reflect the true value measured, ensuring trial results are reliable (Correct answer)

Correct answer: Accurate — data must reflect the true value measured, ensuring trial results are reliable

ALCOA stands for Attributable, Legible, Contemporaneous, Original, and Accurate; 'Accurate' ensures recorded data reflects the true measurement, which is foundational to valid trial results.

Question 36: Under GCP, which of the following is the investigator's responsibility with respect to the investigational product (IP)?

Approving the IP formulation before shipment
Maintaining accountability records for receipt, use, and disposition of the IP (Correct answer)
Manufacturing the IP according to GMP standards
Setting the price of the IP for commercial distribution

Correct answer: Maintaining accountability records for receipt, use, and disposition of the IP

Investigators must maintain accurate accountability records for all investigational product received, dispensed, used, and returned or destroyed.

Question 37: What is the meaning of 'blinding' (or 'masking') in a clinical trial?

A procedure to prevent participants and/or investigators from knowing which treatment is being administered (Correct answer)
The process of randomizing subjects into treatment arms
A method to exclude subjects who do not meet eligibility criteria
The statistical analysis plan for handling missing data

Correct answer: A procedure to prevent participants and/or investigators from knowing which treatment is being administered

Blinding prevents knowledge of treatment assignment to reduce bias; single-blind masks the subject, while double-blind masks both subject and investigator.

Question 38: When a site in the US enrolls a subject without a valid IRB approval, the CRA should first:

Report directly to the FDA without sponsor notification
Notify the sponsor and document the protocol deviation (Correct answer)
Immediately terminate the site
Instruct the site to re-consent the subject

Correct answer: Notify the sponsor and document the protocol deviation

The CRA must notify the sponsor and document the deviation per the monitoring plan; the sponsor then determines escalation steps including possible regulatory reporting.

Question 39: Which of the following is a key item verified during a site qualification visit regarding investigator qualifications?

The investigator's current medical license, CV, and relevant training and experience (Correct answer)
The number of vacation days the investigator takes annually
The investigator's personal financial statements
The investigator's publication count in peer-reviewed journals

Correct answer: The investigator's current medical license, CV, and relevant training and experience

ICH E6 requires that investigators be qualified by education, training, and experience to assume responsibility for trial conduct, which is verified via CV and licensure.

Question 40: Which regulatory submission is typically required in the US BEFORE initiating a Phase I clinical trial with a new investigational drug?

New Drug Application (NDA)
Investigational New Drug (IND) application (Correct answer)
Abbreviated New Drug Application (ANDA)
Biologics License Application (BLA)

Correct answer: Investigational New Drug (IND) application

An IND application must be submitted to the FDA and allowed to proceed (no clinical hold issued within 30 days) before initiating Phase I trials with a new investigational drug in the US.

Question 41: When investigational product is returned from a site for destruction, the CRA must confirm:

The site has purchased replacement supplies
All returned IP is properly labeled, logged, and accompanied by documentation confirming quantities and condition (Correct answer)
The subjects who used the IP have signed an additional consent
The returned IP is tested for potency before destruction

Correct answer: All returned IP is properly labeled, logged, and accompanied by documentation confirming quantities and condition

Returned IP must be documented with quantities matching records, properly labeled, and accompanied by return authorization documentation; this ensures full accountability and proper destruction.

Question 42: Subject diaries used to collect patient-reported outcomes (PROs) are considered:

Source documents, as they represent the original record of subject-reported information (Correct answer)
Not admissible as evidence in regulatory submissions
Secondary data derived from clinical assessments
CRF data only, not source data

Correct answer: Source documents, as they represent the original record of subject-reported information

Subject diaries are source documents because they capture data directly from the subject as the original record, and must be retained according to the same archiving requirements as other source documents.

Question 43: The 'randomization code' in a blinded clinical trial is maintained to:

Reduce the number of placebo-assigned subjects
Ensure balanced age distribution across treatment arms
Allow site coordinators to optimize treatment allocation
Enable emergency unblinding for subject safety and final unblinding for statistical analysis (Correct answer)

Correct answer: Enable emergency unblinding for subject safety and final unblinding for statistical analysis

Randomization codes are securely maintained so they can be accessed in emergencies (e.g., to determine treatment for safety management) and at study end for statistical analysis.

Question 44: Which document serves as the primary agreement between a sponsor and an investigator outlining responsibilities and financial terms for a clinical trial?

Protocol Amendment
Informed Consent Form (ICF)
Investigator Brochure (IB)
Clinical Trial Agreement (CTA) (Correct answer)

Correct answer: Clinical Trial Agreement (CTA)

The Clinical Trial Agreement (CTA) is the legally binding contract between the sponsor and investigator/institution covering obligations, liabilities, and financial terms.

Question 45: An 'adverse event of special interest' (AESI) differs from a standard SAE in that it:

Is always fatal
Can only occur in Phase I trials
Does not require documentation in the CRF
Is predefined in the protocol as requiring expedited reporting regardless of standard seriousness criteria (Correct answer)

Correct answer: Is predefined in the protocol as requiring expedited reporting regardless of standard seriousness criteria

AESIs are protocol-specified events considered scientifically important for the product's benefit-risk assessment and require enhanced or expedited monitoring and reporting even if not classified as serious.

Question 46: During a monitoring visit, a CRA finds a discrepancy between the CRF and source data. The FIRST action should be:

Request a query be raised and ask site staff to correct the CRF with explanation (Correct answer)
Correct the CRF entry directly
Remove the subject from the dataset
Immediately report to the FDA

Correct answer: Request a query be raised and ask site staff to correct the CRF with explanation

Discrepancies should be resolved through the formal query process so that any CRF corrections are made by authorized site staff with appropriate documentation and explanation.

Question 47: Under ICH E6(R2), an investigator must report a serious adverse event to the sponsor:

At the next scheduled monitoring visit
Immediately, typically within 24 hours of learning of the event (Correct answer)
Within 30 days of occurrence
Only if the event is considered related to the study drug

Correct answer: Immediately, typically within 24 hours of learning of the event

ICH E6(R2) section 4.11.1 requires investigators to report SAEs to the sponsor immediately upon learning of the event, except for SAEs exempted in the protocol.

Question 48: Which of the following best describes the Trial Master File (TMF) in the context of site initiation?

A summary document generated only after study completion
A comprehensive collection of essential documents that individually and collectively permit evaluation of the conduct of a trial (Correct answer)
A file containing only the financial agreements between sponsor and site
A database used exclusively by the FDA to evaluate clinical trials

Correct answer: A comprehensive collection of essential documents that individually and collectively permit evaluation of the conduct of a trial

Per ICH E6, the TMF contains essential documents that allow reconstruction of trial conduct and is maintained by both the sponsor and investigator throughout the trial.

Question 49: A 'SUSAR' stands for Suspected Unexpected Serious Adverse Reaction and must meet which THREE criteria?

Serious, severe, and occurring in more than one subject
Serious, unexpected, and possibly related to the investigational product (Correct answer)
Unexpected, life-threatening, and causing hospitalization only
Related, unexpected, and non-serious

Correct answer: Serious, unexpected, and possibly related to the investigational product

A SUSAR must be serious (meets seriousness criteria), unexpected (not in the IB), and have a reasonable suspected causal relationship to the investigational product.

Question 50: According to ICH E6(R2), sponsors must ensure that clinical trials are conducted in accordance with the protocol and GCP. Which mechanism is primarily used to fulfill this oversight obligation?

A monitoring program proportionate to the risk and complexity of the trial (Correct answer)
Mandatory weekly phone calls between CRAs and investigators
Annual IRB review of all site data
Submission of all raw data to FDA for independent review

Correct answer: A monitoring program proportionate to the risk and complexity of the trial

ICH E6(R2) requires sponsors to implement risk-based monitoring programs, scaling oversight intensity to the trial's risk profile and complexity.

Question 51: Dosage and safety (Find out how the medicine affects human metabolism and pharmacology).

Non-refundable start-up fees:
Type of Trial Comparisons?
Primary purpose of a phase 1 study? (Correct answer)
ICH HARMONISED TRIPARTITE GUIDELINE E11

Correct answer: Primary purpose of a phase 1 study?

The primary purpose of a Phase 1 clinical study is to evaluate the safety of a new drug, determine a safe dosage range, and identify potential side effects. These studies also investigate the drug's pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body) in humans. This initial phase helps establish the drug's basic profile in humans.

Question 52: A CRA is reviewing the drug accountability log and notices that the quantity of investigational product dispensed does not reconcile with what subjects received. What should the CRA do?

Flag the discrepancy, discuss with the pharmacist or site coordinator, and document in the monitoring report (Correct answer)
Adjust the log to make the numbers match
Report the site to the FDA without further investigation
Destroy the unaccounted product immediately

Correct answer: Flag the discrepancy, discuss with the pharmacist or site coordinator, and document in the monitoring report

Drug accountability discrepancies must be investigated, discussed with site staff, and documented in the monitoring report to ensure chain of custody.

Question 53: What does 'SUSAR' stand for and what is its significance in clinical trial safety reporting?

Standard Unblinded Safety Adverse Report — a routine safety data submission
Systemic Unexpected Study Adverse Result — a statistical outlier in safety data
Subject Unanticipated Serious Adverse Response — any unexpected hospital admission
Suspected Unexpected Serious Adverse Reaction — an SAE that is both unexpected and causally related to the investigational product (Correct answer)

Correct answer: Suspected Unexpected Serious Adverse Reaction — an SAE that is both unexpected and causally related to the investigational product

A SUSAR is a Suspected Unexpected Serious Adverse Reaction — an SAE with a reasonable causal relationship to the IP that is not consistent with the IB; these have expedited reporting requirements.

Question 54: A sponsor wishes to implement a protocol amendment that changes the primary endpoint. Which regulatory body must approve this amendment before it can be implemented at US sites?

The DSMB and the sponsor's medical monitor
The IRB only
Both the FDA (via IND amendment) and the IRB (Correct answer)
The FDA only

Correct answer: Both the FDA (via IND amendment) and the IRB

Significant protocol changes must be submitted to the FDA as an IND amendment and approved by the site's IRB before implementation.

Question 55: Good Manufacturing Practice (GMP) requirements for investigational products are primarily intended to ensure:

Cost-effective production of clinical supplies
Rapid manufacturing to meet enrollment timelines
Compatibility with commercial packaging standards
Product quality, identity, purity, and potency for subject safety and reliable trial results (Correct answer)

Correct answer: Product quality, identity, purity, and potency for subject safety and reliable trial results

GMP for investigational products (21 CFR Part 211 in the US) ensures that manufacturing processes produce consistent, safe, and accurately labeled product that supports both subject safety and data integrity.

Question 56: Which document is used at site initiation to formally define the delegation of trial-related duties from the Principal Investigator to site staff?

The Protocol Amendment Log
The Delegation of Authority Log (DOA Log) (Correct answer)
The Serious Adverse Event Report
The Informed Consent Form (ICF)

Correct answer: The Delegation of Authority Log (DOA Log)

The Delegation of Authority Log documents which tasks the PI has assigned to specific qualified staff members, ensuring accountability and GCP compliance.

Question 57: When a protocol amendment requires IRB approval before implementation, who is responsible for ensuring the amendment is approved prior to implementation at the site?

The CRO
The Principal Investigator
The Sponsor (Correct answer)
The IRB Chair

Correct answer: The Sponsor

The sponsor is responsible for submitting protocol amendments to the FDA and ensuring IRB approval is in place before the amended protocol is implemented at investigational sites.

Question 58: Unblinding of treatment assignment in a blinded trial for safety reporting purposes should:

Be performed by the CRA for all SAEs
Follow a pre-defined emergency unblinding procedure that minimizes unnecessary unblinding while protecting subject safety (Correct answer)
Require FDA approval before execution
Never occur under any circumstances

Correct answer: Follow a pre-defined emergency unblinding procedure that minimizes unnecessary unblinding while protecting subject safety

Trials should have documented emergency unblinding procedures that allow rapid access to treatment code when medically necessary, while limiting unnecessary unblinding to preserve trial integrity.

Question 59: What is a 'For-Cause Audit' in clinical research?

An unplanned audit triggered by signals of potential fraud, GCP violations, or data integrity concerns (Correct answer)
An audit performed solely for financial compliance
A required pre-submission audit before NDA filing
A scheduled routine audit performed annually

Correct answer: An unplanned audit triggered by signals of potential fraud, GCP violations, or data integrity concerns

A for-cause audit is triggered by specific concerns such as whistleblower reports, unusual data patterns, or serious GCP breaches, and is conducted to investigate the issue in depth.

Question 60: What is the regulatory requirement for corrections made to paper CRF data?

Use white-out to remove the error and write the correct value
Corrections must be made only by the CRA
Draw a single line through the error, write the correct value, initial, and date the correction (Correct answer)
Delete the entire page and resubmit a clean CRF

Correct answer: Draw a single line through the error, write the correct value, initial, and date the correction

GCP requires that CRF corrections preserve the original entry; the correct method is a single line through the error so the original is still legible, with the correction, date, and initials of the person making the change.

Question 61: Who is authorized to dispense investigational product at a clinical trial site?

Any site staff member listed on the trial team list
Any licensed pharmacist regardless of trial training
Only qualified personnel delegated and documented on the Delegation of Authority Log, typically the pharmacist or designated nurse/coordinator (Correct answer)
The CRA during monitoring visits

Correct answer: Only qualified personnel delegated and documented on the Delegation of Authority Log, typically the pharmacist or designated nurse/coordinator

Only personnel specifically trained and authorized on the site's Delegation of Authority Log may dispense IP; this typically requires trial-specific training and pharmacy or nursing qualifications.

Question 62: Which US regulation specifically governs Institutional Review Board (IRB) requirements for FDA-regulated clinical trials?

45 CFR Part 46
21 CFR Part 312
21 CFR Part 50
21 CFR Part 56 (Correct answer)

Correct answer: 21 CFR Part 56

21 CFR Part 56 sets forth the requirements for IRB composition, operations, and review of clinical investigations regulated by the FDA.

Question 63: Which ICH-GCP section outlines the sponsor's responsibilities regarding monitoring?

Section 8 (Essential Documents)
Section 5 (Sponsor) (Correct answer)
Section 6 (Protocol)
Section 4 (Investigator)

Correct answer: Section 5 (Sponsor)

ICH E6(R2) Section 5 covers sponsor responsibilities, including establishing a monitoring system, selecting qualified monitors, and defining monitoring scope and frequency.

Question 64: What is the PRIMARY purpose of a Site Qualification Visit (SQV) conducted by a CRA?

To deliver investigational product to the site pharmacy
To collect completed Case Report Forms from previous studies
To train site staff on the study protocol procedures
To assess the site's capability and resources to conduct the clinical trial (Correct answer)

Correct answer: To assess the site's capability and resources to conduct the clinical trial

The SQV evaluates whether the site has adequate facilities, staff expertise, patient population, and regulatory infrastructure to successfully conduct the trial.

Question 65: When an investigator is taking part in a fresh protocol that has been added to the IND<br> When a fresh researcher is brought into the research

In the guidance, the FDA noted that there are two instances when it is necessary for an investigator to complete and sign a new Form FDA 1572: (Correct answer)
Once an IND application becomes effective, a sponsor-investigator is required to submit the following reports/updates to the FDA.
If a research pharmacy is not available, investigational products can be stored in other areas as long as the following requirements are met
Blister packages (where each drug is placed in an individual plastic dome on a card) enhance compliance in three ways:

Correct answer: In the guidance, the FDA noted that there are two instances when it is necessary for an investigator to complete and sign a new Form FDA 1572:

Form FDA 1572 is a contract between the investigator and the FDA, outlining the investigator's commitments to conduct the study according to the protocol and regulations. The FDA guidance specifies that a new Form 1572 must be completed and signed when a new investigator is added to the research or when an existing investigator participates in a new protocol that has been added to the Investigational New Drug (IND) application.

Question 66: During a site close-out visit, the CRA identifies 15 unused blister packs of investigational product. What is the CORRECT course of action?

Return or destroy the product per the sponsor's instructions and document the reconciliation (Correct answer)
Allow the investigator to keep the product for personal use
Donate the product to a local hospital pharmacy
Leave the product at the site for potential future studies

Correct answer: Return or destroy the product per the sponsor's instructions and document the reconciliation

All unused investigational product must be accounted for and either returned to the sponsor or destroyed per documented procedures to maintain the drug accountability record.

Question 67: What is the primary purpose of the Investigator's Brochure (IB)?

To compile and summarize clinical and nonclinical data relevant to the investigational product for investigators (Correct answer)
To replace the protocol as the definitive trial design document
To serve as the subject recruitment advertisement
To provide financial terms between the sponsor and investigator

Correct answer: To compile and summarize clinical and nonclinical data relevant to the investigational product for investigators

The IB compiles all relevant preclinical and clinical information about the investigational product to inform investigators about risks, properties, and safe use.

Question 68: In electronic clinical trials, 21 CFR Part 11 governs:

The use of electronic records and electronic signatures, ensuring they are trustworthy and equivalent to paper records (Correct answer)
The clinical pharmacology requirements for investigational drugs
The IRB review process for online-recruited subjects
The format of IND application submissions

Correct answer: The use of electronic records and electronic signatures, ensuring they are trustworthy and equivalent to paper records

21 CFR Part 11 establishes FDA requirements for electronic records and signatures to be considered reliable, trustworthy, and equivalent to their paper counterparts, covering audit trails, access controls, and validation.

Question 69: What is the primary purpose of a Clinical Study Report (CSR)?

To document adverse events as they occur during the trial
To provide a comprehensive integrated summary of the methods and results of a clinical trial (Correct answer)
To request IRB approval for a new trial
To inform site staff about protocol changes

Correct answer: To provide a comprehensive integrated summary of the methods and results of a clinical trial

A CSR is a comprehensive document integrating clinical and statistical descriptions and analyses of results, required for regulatory submissions.

Question 70: The principle of 'equipoise' in clinical research ethics means:

Equal compensation for all participants
Genuine uncertainty about which treatment is superior (Correct answer)
Balanced placebo-to-treatment ratio
Equal randomization of subjects

Correct answer: Genuine uncertainty about which treatment is superior

Clinical equipoise refers to genuine uncertainty in the expert medical community about the comparative merits of treatments being studied, justifying the ethical conduct of a trial.

Question 71: Which ICH E6(R2) principle requires that each individual involved in conducting a trial should be qualified by education, training, and experience?

Principle 3 — qualified personnel (Correct answer)
Principle 2 — IRB oversight
Principle 12 — data integrity
Principle 7 — confidentiality protection

Correct answer: Principle 3 — qualified personnel

ICH E6(R2) Principle 3 specifies that all trial personnel must be qualified by education, training, and experience to perform their tasks.

Question 72: From 1932 until 1972, the Tuskegee Syphilis Study was conducted.

No
Yes (Correct answer)

Correct answer: Yes

Yes, the infamous Tuskegee Syphilis Study was indeed conducted from 1932 until 1972 by the U.S. Public Health Service. This study observed the natural progression of untreated syphilis in African American men without their informed consent or offering them available treatment. It stands as a profound example of unethical research, leading to significant reforms in human subject protection and research ethics.

Question 73: Which document formally authorizes a site to begin receiving and storing investigational product?

The Clinical Trial Agreement (financial contract)
The Site Initiation Visit report
The CRA's monitoring plan
A confirmed IRB approval letter, signed protocol, and completed 1572, with sponsor confirmation of site activation (Correct answer)

Correct answer: A confirmed IRB approval letter, signed protocol, and completed 1572, with sponsor confirmation of site activation

A site must have all regulatory and contractual requirements in place — including IRB approval, signed protocol and 1572, and sponsor activation confirmation — before IP can be shipped or dispensed.

Question 74: A 'Competent Authority' in the context of EU clinical trial regulations refers to:

The CRO project manager
The IRB or Ethics Committee
The sponsor's medical monitor
A national regulatory body such as the MHRA or BfArM (Correct answer)

Correct answer: A national regulatory body such as the MHRA or BfArM

A Competent Authority is the national regulatory agency responsible for authorizing clinical trials in a given EU member state, such as the MHRA in the UK or BfArM in Germany.

Question 75: Which document is considered the primary source for verifying that informed consent was obtained before any study procedures were performed?

The investigator's brochure
The subject's enrollment log
The signed and dated informed consent form (Correct answer)
The protocol synopsis

Correct answer: The signed and dated informed consent form

The signed and dated informed consent form is the primary document confirming that consent was obtained prior to study participation.

Question 76: Which practice best ensures blinding integrity during data management activities?

Allowing site coordinators to access treatment assignment codes in the EDC
Sharing treatment assignments with data managers for context
Limiting access to randomization codes to only those who need them for safety monitoring, with all others remaining blinded (Correct answer)
Unblinding all data before database lock for quality review

Correct answer: Limiting access to randomization codes to only those who need them for safety monitoring, with all others remaining blinded

Maintaining blinding integrity requires strict access controls to randomization codes, ensuring that only authorized personnel (e.g., DSMB members, emergency unblinding team) can access treatment assignments.

Question 77: Which ICH E6(R2) addendum concept introduced the idea of proportionate monitoring based on risk?

Source data verification of 100% of CRF entries
Elimination of the Trial Master File requirement
Central monitoring replacing all on-site visits
Risk-based monitoring (RBM) focusing oversight on critical data and processes (Correct answer)

Correct answer: Risk-based monitoring (RBM) focusing oversight on critical data and processes

ICH E6(R2) introduced risk-based monitoring, directing CRA resources toward critical processes and data that have the greatest impact on subject safety and data integrity.

Question 78: What does the term 'source document verification (SDV)' refer to in clinical monitoring?

Checking that the protocol has been approved by the IRB
Creating electronic copies of paper records
Comparing CRF data to original source documents to confirm accuracy (Correct answer)
Verifying the identity of the investigator at the site

Correct answer: Comparing CRF data to original source documents to confirm accuracy

SDV is the process of comparing data recorded in the CRF against original source documents to ensure data accuracy and integrity.

Question 79: A 'comparator product' in a clinical trial refers to:

An approved product (or placebo) used as a reference against which the investigational product is evaluated (Correct answer)
A generic version of the investigational product
A placebo without active ingredients
A backup supply of investigational product

Correct answer: An approved product (or placebo) used as a reference against which the investigational product is evaluated

The comparator is an approved medicinal product or placebo used in a controlled trial to compare against the investigational product's safety and efficacy profile.

Question 80: An IP 'expiry date extension' means:

The protocol enrollment period has been extended
The IRB has approved additional drug use beyond the original period
The site can continue using expired IP if no new supplies are available
The sponsor has performed additional stability testing and obtained regulatory approval to extend the product's use-by date (Correct answer)

Correct answer: The sponsor has performed additional stability testing and obtained regulatory approval to extend the product's use-by date

Expiry extensions require new stability data demonstrating the product remains within specifications, followed by updated labeling and regulatory notification where required.

Question 81: Which of the following is considered an essential document that must be in the investigator's file at the time of site initiation?

The completed final clinical study report
A signed copy of the protocol and all amendments with the date of signature (Correct answer)
The final regulatory submission package for NDA
Copies of all randomization codes for all subjects

Correct answer: A signed copy of the protocol and all amendments with the date of signature

Per ICH E6 Section 8.2, a signed and dated protocol (and amendments) must be in the investigator's file before the trial begins to confirm agreement with study procedures.

Question 82: A subject withdraws consent during a clinical trial. Which of the following best reflects the investigator's obligations regarding that subject's already-collected data?

All data collected must be destroyed immediately upon withdrawal
Previously collected data may generally be retained and used per the informed consent signed at enrollment (Correct answer)
The sponsor must seek new consent from the subject to retain any data
The subject's data must be excluded from all analyses regardless of consent language

Correct answer: Previously collected data may generally be retained and used per the informed consent signed at enrollment

Data collected prior to withdrawal may typically be retained and used as described in the original ICF; subjects can withdraw from further participation but cannot generally require retroactive data deletion in regulated trials.

Question 83: A subject reports a new, unexpected, drug-related serious adverse event. According to ICH E6, within what timeframe must the investigator report this to the sponsor?

Within 7 calendar days
Within 48 hours of becoming aware
Within 24 hours of becoming aware (Correct answer)
Within 15 calendar days

Correct answer: Within 24 hours of becoming aware

ICH E6(R2) requires investigators to report all serious adverse events to the sponsor immediately, and no later than 24 hours of their becoming aware of the event.

Question 84: Any type of legal body, such as a business, a nonprofit group, or an individual, may serve as _______

Lis Pendens
Principal
Institution
Sponsor (Correct answer)

Correct answer: Sponsor

In clinical research, the 'Sponsor' is the individual, company, institution, or organization that takes responsibility for the initiation, management, and/or financing of a clinical trial. The sponsor is ultimately accountable for the overall conduct of the study and compliance with regulatory requirements. This entity oversees the entire research process.

Question 85: Site staff may not open or break the blind of randomization codes except:

When the CRA requests unblinding during a monitoring visit
After enrollment of the first 10 subjects for interim safety review
When a subject requests to know their treatment assignment
When medically necessary for subject safety (e.g., medical emergency) following the pre-defined emergency unblinding procedure (Correct answer)

Correct answer: When medically necessary for subject safety (e.g., medical emergency) following the pre-defined emergency unblinding procedure

Emergency unblinding is permitted only when knowledge of treatment is medically necessary to protect the subject, and must follow a documented procedure with notification to the sponsor.

Question 86: Under FDA regulations, what is required when a sponsor makes a 'major' change to an approved IND protocol?

Only IRB approval is needed, not FDA notification
No notification is required for protocol changes
A protocol amendment must be submitted to the FDA before implementing the change (Correct answer)
The sponsor can implement the change after notifying the FDA within 30 days

Correct answer: A protocol amendment must be submitted to the FDA before implementing the change

Major protocol amendments under an IND must be submitted to FDA prior to implementation, as they may affect subject safety or study integrity.

Question 87: During a site close-out visit, the CRA confirms all queries are resolved. What is the FINAL step before the site is officially closed?

The site is notified in writing that close-out is complete and records must be archived for the required retention period (Correct answer)
The CRA transfers all site data to another active clinical site
The PI submits a new IND for a follow-up study
The CRA collects all IRB correspondence and destroys it

Correct answer: The site is notified in writing that close-out is complete and records must be archived for the required retention period

Official close-out is confirmed by written notification to the site, reminding the investigator of archiving obligations and the required document retention period.

Question 88: When a clinical trial uses an interactive response technology (IRT/IVRS/IWRS) system for randomization and IP management, the system's primary functions include:

Managing subject randomization, treatment assignment, and investigational product dispensing and resupply logistics (Correct answer)
Submitting regulatory documents to the FDA
Generating adverse event reports automatically
Tracking site monitoring visit schedules

Correct answer: Managing subject randomization, treatment assignment, and investigational product dispensing and resupply logistics

IRT systems (IVRS for voice, IWRS for web) are used to randomize subjects, assign treatment, manage IP kit assignment, and trigger resupply orders based on site inventory levels.

Question 89: When the investigator's causality assessment differs from the sponsor's (sponsor considers event related, investigator does not), how should the discrepancy be handled for regulatory reporting?

The event does not need to be reported if the investigator disagrees
A data safety monitoring board must resolve all discrepancies before reporting
Both assessments should be reported, with the sponsor reporting based on the more conservative (related) assessment (Correct answer)
The investigator's assessment always overrides the sponsor's

Correct answer: Both assessments should be reported, with the sponsor reporting based on the more conservative (related) assessment

Regulatory guidance requires that when sponsor and investigator causality assessments differ, both must be documented, and the more conservative (causally related) assessment governs regulatory reporting requirements.

Question 90: When a CRA finds that a site has enrolled a subject who did not meet all inclusion criteria, this is documented as:

An adverse event
A serious breach of confidentiality
A protocol deviation or violation (Correct answer)
An investigational product discrepancy

Correct answer: A protocol deviation or violation

Enrolling a subject who fails to meet inclusion criteria is a protocol deviation (or violation if major), which must be documented, reported to the sponsor, and may require IRB notification.

Question 91: Subject medication compliance (adherence) is most commonly assessed in clinical trials by:

Sponsor review of financial payment records
Investigator opinion during clinic visits
Pill/device counts, subject diaries, or plasma drug level measurements (Correct answer)
Subject self-report at final visit only

Correct answer: Pill/device counts, subject diaries, or plasma drug level measurements

Compliance is typically measured through returned pill counts, patient diary records of doses taken, and/or pharmacokinetic sampling to confirm drug exposure, as specified in the protocol.

Question 92: Define pharmacokinetics.

The monitoring guidelines are ICH-GCP Guidelines and FDA Guidelines
The normal care provided per the sites guidelines
The study of drug movement throughout the body (Correct answer)
Via Web

Correct answer: The study of drug movement throughout the body

Pharmacokinetics is a branch of pharmacology that describes how the body affects a drug. It specifically focuses on the processes of absorption, distribution, metabolism, and excretion (ADME) of a drug within the body. Understanding pharmacokinetics is crucial for determining appropriate drug dosages and regimens.

Question 93: What is the role of the Data Safety Monitoring Board (DSMB) in a clinical trial?

To conduct site inspections on behalf of the FDA
To approve the protocol before the trial begins
To independently review accumulating safety and efficacy data and recommend continuation, modification, or termination of the trial (Correct answer)
To manage the randomization schedule for subjects

Correct answer: To independently review accumulating safety and efficacy data and recommend continuation, modification, or termination of the trial

A DSMB is an independent committee that periodically reviews unblinded data to protect the safety of trial participants and the validity of the trial.

Question 94: A 'certified copy' of a source document is acceptable when:

It is signed only by the CRA
The original document has been destroyed
It is a verified copy that has been confirmed as an exact copy of the original through a documented process (Correct answer)
It is created by the CRA during the monitoring visit

Correct answer: It is a verified copy that has been confirmed as an exact copy of the original through a documented process

A certified copy is a copy verified to be a true and accurate copy of the original through a documented certification process, and it may be retained in place of the original when needed.

Question 95: What is the difference between an Adverse Event (AE) and an Adverse Drug Reaction (ADR)?

An AE requires hospitalization while an ADR does not
An AE is always more serious than an ADR
An ADR implies at least a possible causal relationship to the study drug, while an AE does not require causality (Correct answer)
An ADR applies only to marketed drugs, not investigational products

Correct answer: An ADR implies at least a possible causal relationship to the study drug, while an AE does not require causality

An AE is any untoward medical occurrence temporally associated with study drug use, regardless of causality; an ADR implies a causal relationship has been at least reasonably suspected.

Question 96: Which GCP principle states that the rights, safety, and well-being of trial subjects are the most important considerations?

Data integrity principle
Scientific validity principle
Ethical principle of primacy of subject protection (Correct answer)
Principle of equipoise

Correct answer: Ethical principle of primacy of subject protection

ICH E6(R2) principle 2.3 explicitly states that the rights, safety, and well-being of trial subjects must prevail over the interests of science and society.

Question 97: Analysis of all trial participants who followed procedure and finished the experiment

repeated measures
blinding of the researchers
per protocol analysis (Correct answer)
bayesian approaches

Correct answer: per protocol analysis

Per-protocol analysis (PPA) includes only those participants who completed the study exactly as planned, adhered to the study protocol, and did not have major protocol deviations. This analysis provides an estimate of the treatment effect under ideal conditions, focusing on participants who fully complied with the intervention. It contrasts with intention-to-treat analysis, which includes all randomized participants.

Question 98: Which ICH-GCP guideline governs the conduct of clinical trials to ensure data integrity and subject safety?

ICH E8
ICH E9
ICH E3
ICH E6(R2) (Correct answer)

Correct answer: ICH E6(R2)

ICH E6(R2) is the Good Clinical Practice guideline that establishes international standards for designing, conducting, recording, and reporting trials involving human subjects.

Question 99: Which entity is responsible for assessing the causality (relatedness) of an adverse event to the investigational product?

The subject or patient
The CRA during the monitoring visit
The IRB during the annual review
The investigator, and separately the sponsor's medical monitor (Correct answer)

Correct answer: The investigator, and separately the sponsor's medical monitor

Both the investigator and the sponsor's medical monitor independently assess causality; both assessments must be documented and both can be required in regulatory reports.

Question 100: In clinical data management, 'edit checks' are used to:

Validate data entries against predefined rules to detect out-of-range values, missing data, or logical inconsistencies (Correct answer)
Grant data entry permissions to site coordinators
Send regulatory submissions automatically
Correct CRF data automatically without site input

Correct answer: Validate data entries against predefined rules to detect out-of-range values, missing data, or logical inconsistencies

Edit checks (or validation rules) are programmed into EDC systems to flag data that is missing, illogical, or outside expected ranges, prompting review or generating queries.

Question 101: During a monitoring visit, a CRA notices the Delegation of Authority Log does not include a recently added sub-investigator. The BEST action is to:

Remove the sub-investigator from all future trial activities
Submit a protocol deviation on behalf of the site
Perform the visit as planned and note it as a non-issue
Require the PI to update the log before the sub-investigator performs any further trial-related activities (Correct answer)

Correct answer: Require the PI to update the log before the sub-investigator performs any further trial-related activities

All personnel performing trial-related duties must be listed on the Delegation of Authority Log; the PI must update it immediately to maintain GCP compliance before the sub-investigator continues trial activities.

Question 102: What is the purpose of an annual Development Safety Update Report (DSUR)?

To report financial expenditures to regulatory agencies
To submit enrollment data to the trial registry
To provide a comprehensive annual review of the investigational product's safety profile and risk-benefit assessment (Correct answer)
To document site initiation activities for the year

Correct answer: To provide a comprehensive annual review of the investigational product's safety profile and risk-benefit assessment

The DSUR (guided by ICH E2F) is submitted annually to regulatory authorities during clinical development to summarize worldwide safety experience and the current benefit-risk profile.

Question 103: When must the CRA ensure that the Trial Master File (TMF) is set up and accessible?

Only during regulatory inspections
Before the trial begins and maintained throughout the trial (Correct answer)
After the database is locked
Only after the first subject is enrolled

Correct answer: Before the trial begins and maintained throughout the trial

ICH E6(R2) requires the TMF to be established before the trial commences and maintained throughout the trial and post-trial period.

Question 104: What is the primary purpose of the Declaration of Helsinki?

To establish FDA regulatory requirements for drug approval
To set standards for statistical analysis in clinical trials
To provide ethical principles for medical research involving human subjects (Correct answer)
To define Good Manufacturing Practice (GMP) requirements

Correct answer: To provide ethical principles for medical research involving human subjects

The Declaration of Helsinki is a foundational ethical document developed by the World Medical Association to guide researchers conducting studies involving human participants.

Question 105: What documentation must you submit in order to participate in a clinical research study?

Protocol
Informed Consent Form (Correct answer)
Investigator's Brochure
Case Report Form

Correct answer: Informed Consent Form

To participate in any clinical research study, every potential subject must submit an Informed Consent Form (ICF). This crucial document ensures that individuals are fully informed about the study's purpose, procedures, potential risks, and benefits before voluntarily agreeing to participate. Signing the ICF is a fundamental ethical and regulatory requirement designed to protect the rights and welfare of human subjects.

Question 106: What percentage of SDV is typically used in a traditional 100% SDV monitoring approach?

100% of all CRF data compared to source documents (Correct answer)
50% of safety data only
25% of critical data fields
10% random sampling of all data

Correct answer: 100% of all CRF data compared to source documents

Traditional monitoring required 100% SDV of all CRF data against source documents, though modern risk-based approaches allow reduced SDV targeting critical data only.

Question 107: A 'data management plan' (DMP) in a clinical trial typically includes:

Investigational product manufacturing specifications
The statistical analysis plan for primary endpoints only
Database design, data collection procedures, validation rules, and quality control processes for the trial's data (Correct answer)
Subject recruitment and retention strategies

Correct answer: Database design, data collection procedures, validation rules, and quality control processes for the trial's data

The DMP outlines how data will be collected, validated, cleaned, and managed throughout the trial, covering EDC configuration, query management, coding, and database lock procedures.

Question 108: A subject experiences a Serious Adverse Event (SAE) on a Monday. Within what timeframe must the investigator report an unexpected, fatal SAE to the sponsor under ICH E6(R2)?

Within 24 hours
Within 7 calendar days (Correct answer)
Within 15 business days
Within 30 calendar days

Correct answer: Within 7 calendar days

ICH E6(R2) requires investigators to report fatal or life-threatening unexpected SAEs to the sponsor within 7 calendar days of first awareness.

Question 109: Under FDA 21 CFR Part 312, the sponsor must notify the FDA of an IND safety report (IND Safety Report) within how many calendar days for unexpected fatal or life-threatening SUSARs?

7 calendar days (Correct answer)
30 calendar days
45 calendar days
15 calendar days

Correct answer: 7 calendar days

Fatal or life-threatening unexpected serious adverse reactions must be reported to the FDA within 7 calendar days of the sponsor's first knowledge.

Question 110: Which of the following items is the CRA responsible for confirming is in place at site initiation before the first subject is enrolled?

Completed study report, database lock, and regulatory approval of the final label
IRB approval, signed protocol, delegation log, trained staff, and available investigational product (Correct answer)
Subject payment schedules and insurance documentation only
Phase IV commitments, post-approval studies, and marketing authorization

Correct answer: IRB approval, signed protocol, delegation log, trained staff, and available investigational product

Before first enrollment, the CRA must verify all regulatory approvals, site agreements, staff training, delegation of authority, and product availability are in place.

Question 111: When a laboratory value is flagged outside the reference range, the investigator must:

Immediately discontinue the subject from the trial
Delete the value from the CRF and re-draw the sample
Clinically evaluate the result, document their assessment, and determine whether it is clinically significant (Correct answer)
Report it as an SAE regardless of clinical significance

Correct answer: Clinically evaluate the result, document their assessment, and determine whether it is clinically significant

Out-of-range lab values require the investigator to make a clinical significance determination; if clinically significant, appropriate action (including possible AE reporting) must follow and be documented.

Question 112: Which of the following best describes 'open-label' trial design with respect to investigational product management?

IP is provided with no label or identification
The IP label includes the subject's name publicly
Only the subject is unblinded while the investigator remains blinded
Both subjects and investigators know which treatment is being administered, with no blinding of treatment assignment (Correct answer)

Correct answer: Both subjects and investigators know which treatment is being administered, with no blinding of treatment assignment

In an open-label trial, there is no blinding — both the subject and the site staff know which treatment the subject is receiving, simplifying IP management but introducing potential bias.

Question 113: What is the definition of 'source data' according to ICH E6(R2)?

Randomization codes held by the unblinded statistician
Original records and certified copies of original records of clinical findings, observations, or other activities in a clinical trial (Correct answer)
Data that has been verified and approved by the sponsor's data management team
Data entered directly into the electronic CRF by the site coordinator

Correct answer: Original records and certified copies of original records of clinical findings, observations, or other activities in a clinical trial

Source data includes all original records (e.g., hospital records, lab printouts, diaries) and certified copies that document clinical trial activities.

Question 114: When investigational product is transferred between two investigational sites, which step is MOST critical?

Confirming both sites are in the same city
Allowing the CRA to transport the product during a monitoring visit
Ensuring the receiving site has a lower temperature during transit
Obtaining sponsor approval and ensuring complete chain of custody documentation with temperature monitoring during transfer (Correct answer)

Correct answer: Obtaining sponsor approval and ensuring complete chain of custody documentation with temperature monitoring during transfer

Site-to-site IP transfers require sponsor authorization and complete documentation of the chain of custody, including temperature conditions during transit, to maintain product integrity and accountability.

Question 115: In the US, a sponsor must submit an IND application to the FDA before:

Shipping investigational drug to sites
Initiating a Phase I clinical trial in humans
Both B and C (Correct answer)
Publishing trial results

Correct answer: Both B and C

An IND must be submitted before shipping investigational drug and before initiating a clinical trial in human subjects in the United States.

Question 116: What distinguishes a Serious Adverse Event (SAE) from a non-serious adverse event?

An SAE results in death, is life-threatening, requires hospitalization, results in disability, or involves a congenital anomaly (Correct answer)
An SAE requires statistical significance to be classified as serious
An SAE is any adverse event reported by the subject
An SAE must always be caused by the investigational product

Correct answer: An SAE results in death, is life-threatening, requires hospitalization, results in disability, or involves a congenital anomaly

An SAE meets at least one of the seriousness criteria defined in ICH E2A: death, life-threatening, inpatient hospitalization, persistent disability, congenital anomaly, or other medically important event.

Question 117: A CRA performs a remote/centralized monitoring review and notices an unusual clustering of perfect protocol adherence at one site compared to all others. What should this trigger?

A data integrity investigation and possible for-cause monitoring visit to rule out data fabrication (Correct answer)
Immediate database lock for that site's data
Notification to the IRB that the site can enroll additional subjects
Recognition of the site as a top performer and reduction of monitoring visits

Correct answer: A data integrity investigation and possible for-cause monitoring visit to rule out data fabrication

Statistically improbable patterns such as perfect adherence are a red flag for potential data fabrication and warrant a targeted for-cause visit and data integrity investigation.

Question 118: What is the function of a Study Coordinator Certification (e.g., CCRC from ACRP) compared to the CCRA certification?

Both certifications are identical and interchangeable in clinical research roles
CCRC is only relevant for oncology trials; CCRA applies to all therapeutic areas
CCRC certifies site-level coordinators supporting investigators, while CCRA certifies sponsor/CRO monitors overseeing site compliance (Correct answer)
CCRA certifies site coordinators; CCRC certifies sponsor monitors

Correct answer: CCRC certifies site-level coordinators supporting investigators, while CCRA certifies sponsor/CRO monitors overseeing site compliance

CCRC (Certified Clinical Research Coordinator) is for site staff supporting investigators, whereas CCRA is for clinical monitors employed by sponsors or CROs.

Question 119: What is the purpose of an Investigator Brochure (IB) in a clinical trial?

To obtain regulatory approval to conduct the trial
To document the subject's consent to participate
To outline the statistical analysis plan for the study
To provide investigators with clinical and nonclinical data about the investigational product (Correct answer)

Correct answer: To provide investigators with clinical and nonclinical data about the investigational product

The IB compiles relevant preclinical and clinical information about an investigational product to guide investigators in safely conducting the trial.

Question 120: Which element is NOT required to be included in an informed consent form according to 21 CFR Part 50.25?

A description of foreseeable risks or discomforts
A statement that participation is voluntary
The subject's social security number (Correct answer)
The expected duration of the subject's participation

Correct answer: The subject's social security number

21 CFR 50.25 lists required ICF elements, and a subject's social security number is not among them; collecting it would be a privacy concern.

Question 121: What action should a CRA take if a site refuses to correct a major protocol deviation identified during a monitoring visit?

Accept the site's position and close out the visit without further action
Contact the FDA directly to report the site without notifying the sponsor
Personally correct the deviation by altering the site's records
Escalate the issue to the sponsor's management and document the refusal in the monitoring report (Correct answer)

Correct answer: Escalate the issue to the sponsor's management and document the refusal in the monitoring report

When a site refuses corrective action, the CRA must document the refusal and escalate to sponsor management, who may involve regulatory authorities or terminate the site.

Question 122: Which document type serves as the definitive guide for CRAs on how to perform site visits for a specific trial?

Clinical Study Report
Investigator Brochure
Monitoring Plan (Correct answer)
Site Initiation Checklist

Correct answer: Monitoring Plan

The Monitoring Plan specifies the monitoring strategy, methodology, responsibilities, and procedures to be followed during trial monitoring visits.

Question 123: In the context of a clinical trial, what does 'randomization' achieve?

It eliminates the need for a control group
It ensures all subjects receive the same treatment
It reduces selection bias by ensuring subjects are assigned to treatment groups by chance (Correct answer)
It determines which sites are selected to participate in the trial

Correct answer: It reduces selection bias by ensuring subjects are assigned to treatment groups by chance

Randomization minimizes selection bias and helps ensure that treatment groups are comparable by assigning subjects to groups by chance rather than choice.

Question 124: During a Site Initiation Visit (SIV), which of the following is the CRA's MOST critical responsibility?

Ensuring all site staff are trained and documented on the protocol before enrollment begins (Correct answer)
Submitting the final Clinical Study Report to the IRB
Requesting a list of all patients who may be eligible for the study
Reviewing all previously published literature on the investigational product

Correct answer: Ensuring all site staff are trained and documented on the protocol before enrollment begins

The SIV ensures all site personnel are adequately trained and that training documentation is complete before the first subject is enrolled.

Question 125: How many steps are involved in the conduct of a clinical research study?

2
1
3
4 (Correct answer)

Correct answer: 4

Clinical research studies are typically conducted in four distinct phases: Phase I, Phase II, Phase III, and Phase IV. Phase I focuses on safety and dosage in a small group of healthy volunteers. Phase II evaluates efficacy and side effects in a larger group of patients. Phase III confirms efficacy, monitors adverse reactions, and compares the new treatment to existing ones in large populations. Phase IV involves post-marketing surveillance after regulatory approval.

CCRA® — Certified Clinical Research Associate

The CCRA® credential, offered by ACRP, validates the knowledge and skills of clinical research associates who monitor clinical trials to ensure GCP compliance, participant safety, data integrity, and regulatory adherence across all phases of drug and device development.

125

Questions

180 min

Time Limit

70%

To Pass

Checking for saved progress...

Exam Rules

You can skip questions and return to them later
Flag questions for review before submitting
No feedback shown until you submit the entire exam
Unanswered questions count as wrong — answer everything
10 pretest questions are mixed in and don't affect your score
Timer auto-submits when time runs out
Your progress is auto-saved every 30 seconds